{"commentary":{"count":142,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":102,"podcast":21,"youtube":19},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03972488\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NETTER-2","nct_id":"NCT03972488","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=netter-2-nct03972488. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"NETTER-2","arms":[{"description":"Lutathera treatment consisted of a cumulative administered radioactivity of 29.6 GBq (800mCi) (7.4 GBq/200 mCi x 4 administrations every 8 +/- 1 week). Participants in the Lutathera arm were concomitantly administered with octreotide LAR 30 mg (Sandostatin LAR Depot) the day after each administration of Lutathera and no earlier than 4 hours after completion of the Lutathera infusion. Once Lutathera treatment completed, participants continued the 4-week interval administrations of 30 mg octreotide LAR until the completion of the Treatment Phase. Concomitantly with Lutathera, sterile amino acid solution was administered to minimize renal radiation exposure during Lutathera treatment.","label":"Lutathera® plus Octreotide LAR 30 mg (Investigational arm)","type":"EXPERIMENTAL"},{"description":"Participants were administered with octreotide LAR 60 mg (Sandostatin LAR Depot) at 4-week intervals until the completion of the Treatment Phase.","label":"Octreotide LAR 60 mg (Control arm)","type":"ACTIVE_COMPARATOR"},{"description":"Participants who received Lutathera in experimental arm and who progressed and met re-treatment eligibility criteria received additional 2 - 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles)","label":"Optional post-progression re-treatment with Lutathera","type":"EXPERIMENTAL"},{"description":"Participants who received Octreotide LAR in Active comparator arm and who progressed and met cross-over eligibility criteria received maximum 4 cycles of Lutaathera (7.4 GBq/200 mCi x 4 cycles) plus octreotide long-acting (30 mg every 8 weeks).","label":"Optional post-progression cross-over to Lutathera","type":"ACTIVE_COMPARATOR"},{"description":"Participants who received Octreotide LAR in Active comparator arm subsequently entered cross-over, received Lutathera in cross-over, progressed for the second time and met re-treatment eligibility criteria could receive additional 2 - 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles).","label":"Optional post-progression re-treatment with Lutathera after cross-over","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-10-29","type":"ESTIMATED"},"conditions":["Gastro-enteropancreatic Neuroendocrine Tumor"],"enrollment":{"count":226,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lutathera","type":"DRUG"},{"name":"30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)","type":"DRUG"},{"name":"2.5% Lys-Arg sterile amino acid solution","type":"DRUG"},{"name":"High dose 60 mg octreotide long-acting repeatable","type":"DRUG"}],"last_update":"2026-01-21","lead_sponsor":"Advanced Accelerator Applications","official_title":"A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-07-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) Per Central Assessment","timeFrame":"from randomization to the first line progression or death due to any cause, up to approx. 42 months"}],"references":[{"citation":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garcia-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.","pmid":"38851203","type":"RESULT"},{"citation":"Ferone D, Pavel M, Herrmann K, Kunz PL, Myrehaug S, Halperin D, Chasen B, Capdevila J, Garcia-Burillo A, Tafuto S, Lastoria S, Oh DY, Yoo C, Falk S, Halfdanarson TR, Sansovini M, Gerard L, Deshayes E, Filice A, Folitar I, Zhang Y, de Herder WW, Singh S. [177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial. EClinicalMedicine. 2026 Aug 7;98:104109. doi: 10.1016/j.eclinm.2026.104109. eCollection 2026 Aug.","pmid":"42604001","type":"DERIVED"},{"citation":"Holzgreve A, Unterrainer LM, Tiling M, Mansour N, Spitzweg C, Brendel M, Ricke J, Unterrainer M, Kunz WG, Mehrens D. Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trial. J Nucl Med. 2025 Jul 1;66(7):1075-1081. doi: 10.2967/jnumed.124.269416.","pmid":"40473457","type":"DERIVED"},{"citation":"Bahri N, Crook C, Daneng Li. Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment? Oncology (Williston Park). 2024 Nov 5;38(11):442-443. doi: 10.46883/2024.25921029.","pmid":"39570708","type":"DERIVED"},{"citation":"Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.","pmid":"33973550","type":"DERIVED"}],"start_date":{"date":"2020-01-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","url":"https://clinicaltrials.gov/study/NCT03972488"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/netter-2-nct03972488"}